| Literature DB >> 35276497 |
Virginia Protto1, Maria Elena Marcocci1, Mariya Timotey Miteva1, Roberto Piacentini2, Domenica Donatella Li Puma2, Claudio Grassi2, Anna Teresa Palamara3, Giovanna De Chiara4.
Abstract
Herpes simplex virus-1 (HSV-1) is a ubiquitous DNA virus able to establish a life-long latent infection in host sensory ganglia. Following periodic reactivations, the neovirions usually target the site of primary infection causing recurrent diseases in susceptible individuals. However, reactivated HSV-1 may also reach the brain resulting in severe herpetic encephalitis or in asymptomatic infections. These have been reportedly linked to neurodegenerative disorders, such as Alzheimer's disease (AD), suggesting antiviral preventive or/therapeutic treatments as possible strategies to counteract AD onset and progression. Here, we provide an overview of the AD-like mechanisms driven by HSV-1-infection in neurons and discuss the ongoing trials repurposing anti-herpetic drugs to treat AD as well as preventive strategies aimed at blocking virus infection.Entities:
Mesh:
Year: 2022 PMID: 35276497 DOI: 10.1016/j.coph.2022.102200
Source DB: PubMed Journal: Curr Opin Pharmacol ISSN: 1471-4892 Impact factor: 5.547